Cycloferon tab. p / o c / w sol. 150mg # 10

Release form, composition and packaging

Enteric-coated yellow tablets, round, biconvex

cross section - yellow core.

1 tab.

meglumine acridone acetate (in terms of acridoneacetic acid)

150 mg

povidone - 7.93 mg, calcium stearate - 3.07 mg, hypromellose - 2.73 mg, polysorbate 80 - 0.27 mg, copolymer of methacrylic acid and ethyl acrylate - 23.21 mg, propylene glycol - 1.79 mg.

10 pieces.

- contour cell packaging (1) - cardboard packs.

10 pieces.

- contour cell packaging (5) - cardboard packs.

20 pcs.

- contoured cell packaging (1) - cardboard packs. Pharmacological action Cycloferon is a low molecular weight inducer of interferon, which determines a wide range of its biological activity (antiviral, immunomodulating, anti-inflammatory).

Cycloferon is effective against herpes viruses, influenza and other pathogens of acute respiratory diseases.

It has a direct antiviral effect, suppressing the reproduction of the virus in the early stages (1-5 days) of the infectious process, reducing the virulence of the viral progeny, leading to the formation of defective viral particles.

Increases the body's nonspecific resistance to viral and bacterial infections. Pharmacokinetics

After taking the drug orally in a daily dose in blood plasma, it is reached after 2-3 hours, the concentration gradually decreases by 8 hours, after 24 hours the active substance is found in trace amounts.

Withdrawal

T1 / 2 is 4-5 hours. The use of the drug Cycloferon in recommended doses does not create conditions for its accumulation in the body. Indications for use As part of complex therapy in adults:

flu and acute respiratory infections

herpes infection.

As part of complex therapy in children aged 4 years and older:

flu and acute respiratory infections

herpes infection.

Prevention of influenza and acute respiratory diseases in children aged 4 years and older. Contraindications to the use of liver cirrhosis in the stage of decompensation

children under 4 years of age (due to imperfect swallowing)

pregnancy

period of breastfeeding

individual intolerance to the components of the drug.

The drug should be used with caution in diseases of the digestive system in the acute phase (erosion, gastric and / or duodenal ulcers, gastritis, duodenitis) and a history of allergic reactions.

Before taking the drug, patients with these diseases should consult a doctor. Dosing regimen The drug is taken orally 1 time / day 30 minutes before meals, without chewing, drinking 1/2 glass of water.

The dose of the drug depends on the age of the patient.

Adults and children over 12 years of age are prescribed 450-600 mg (3-4 tablets) per appointment.

Children aged 7-11 years are prescribed 300-450 mg (2-3 tablets) per appointment.

Children aged 4-6 years are prescribed 150 mg (1 tab.) For admission.

It is advisable to repeat the course 2-3 weeks after the end of the first course.

Adults

In the treatment of influenza and acute respiratory diseases, the drug should be taken on the 1st, 2nd, 4th, 6th, 8th day (course of treatment - 20 tab.).

Treatment should be started at the first symptoms of the disease.

In case of severe flu, 6 tablets should be taken on the 1st day.

drug.

If necessary, symptomatic therapy is additionally carried out (antipyretic, analgesic, expectorant drugs).

In case of herpes infection, the drug should be taken on 1, 2, 4, 6, 8, 11, 14, 17, 20, 23 days (course of treatment - 40 tab.) Treatment is most effective when the first symptoms of the disease appear.

Children aged 4 and over

In the treatment of influenza and acute respiratory diseases, prep

Name ENG

CYCLOFERON

Clinical and pharmacological group

Antiviral and immunomodulatory drug.

Interferon synthesis inductor

ATX code

Other immunostimulants

Dosage

150mg

Structure

1 tablet contains: active ingredient: meglumine acridone acetate in terms of acridone acetic acid - 150 mg

excipients: povidone - 7.93 mg, calcium stearate - 3.07 mg, hypromellose - 2.73 mg, polysorbate 80 - 0.27 mg, methacrylic acid and ethyl acrylate copolymer - 23.21 mg, propylene glycol - 1.79 mg ...

Indications

As part of complex therapy in adults:

flu and acute respiratory infections

herpes infection.

As part of complex therapy in children aged 4 years and older:

flu and acute respiratory infections

herpes infection.

Prevention of influenza and acute respiratory diseases in children aged 4 years and older.

INN / Active ingredient

acridoneacetic acid

Storage conditions and periods

In a dark place at a temperature not exceeding 25 degrees.

Expiration date: 2 years

Contraindications

cirrhosis of the liver in the stage of decompensation

children under 4 years of age (due to imperfect swallowing)

pregnancy

period of breastfeeding

individual intolerance to the components of the drug.

The drug should be used with caution in diseases of the digestive system in the acute phase (erosion, gastric and / or duodenal ulcers, gastritis, duodenitis) and a history of allergic reactions.

Before taking the drug, patients with these diseases should consult a doctor.

Specifications

Category

Antiviral

,

Antimicrobial agents

Scope of the drug

General

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

ten

Minimum age from

4 years old

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Polisan

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Immunostimulating agent

Anatomical and therapeutic characteristics

L03AX Other immunostimulants

Dosage form

Enteric-coated tablets

Expiration date in days

730

The target audience

Children

Package weight, g

5

Mode of application

:

Inside, once a day, 30 minutes before meals, without chewing, drinking 1/2 glass of water, in age dosages: for children 4-6 years old: 150 mg (1 tablet) per dose < br> for children 7-11 years old: 300-450 mg (2-3 tablets) per dose < br> adults and children over 12 years old: 450-600 (3-4 tablets) per dose. < br> A repeated course is advisable to carry out 2-3 weeks after the end of the first course. < br> In adults: < br> 1. When treating influenza and acute respiratory diseases, the drug is taken on the 1st, 2, 4, 6, 8th days (course of treatment - 20 tablets). Treatment should be started at the first symptoms of the disease. < br> In case of severe flu, six tablets are taken on the first day. If necessary, additional symptomatic therapy (antipyretic, analgesic, expectorant drugs) is carried out. < br> 2.In case of herpes infection, the drug is taken on the 1st, 2nd, 4th, 6th, 8th, 11th, 14th, 17th, 20th and 23rd days (the course of treatment is 40 tablets). Treatment is most effective when the first symptoms of the disease appear. < br> In children from four years of age: < br> 1. For influenza and acute respiratory diseases, the drug is taken in age doses at 1, 2, 4, 6, 8, 11, 14, 17, 20, 23 days. The course of treatment is from 5 to 10 doses, depending on the severity of the condition and the severity of clinical symptoms. < br> 2. In case of herpes infection, the drug is taken on the 1st, 2nd, 4th, 6th, 8th, 11th, 14th days of treatment. The course of treatment may vary depending on the severity of the condition and the severity of the clinical symptoms. < br> 3.For emergency nonspecific prophylaxis of influenza and acute respiratory diseases (with direct contact with patients with influenza or acute respiratory infections of a different etiology, during an influenza epidemic): on the 1st, 2nd, 4th, 6th, 8th day. Then take a break of 72 hours (three days) and continue the course for 11, 14, 17, 20, 23 days. The general course is from 5 to 10 receptions.

Dosage (volume) of the substance in the preparation

:

Meglumine acridone acetate in terms of acridoneacetic acid - 150 mg

Information on technical characteristics, delivery set, country of manufacture